AGILE THERAPEUTICS INC
AGRX, AGXRWHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $19.6M | $10.9M | $4.1M | $749,000 | $0 | $0 |
| Operating income | −$19.9M | −$52.6M | −$71.0M | −$49.1M | −$18.9M | −$19.5M |
| Net income | −$14.5M | −$25.4M | −$71.1M | −$51.9M | −$18.6M | −$19.8M |
| Total assets | $10.3M | $14.2M | $39.3M | $73.1M | $49.5M | $22.4M |
| Total liabilities | $26.6M | $19.8M | $35.4M | $23.7M | $3.8M | $2.2M |
| Equity | −$16.3M | −$5.5M | $3.9M | $49.3M | $45.7M | $20.2M |
| EPS (diluted) | $-6.71 | $-58.79 | $-1464.20 | $-24.40 | $-0.38 | — |
| Shares out. | 46.5M | 134.6M | 87.6M | 69.8M | 43.2M | 34.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −101.5%
- Net margin
- −73.8%
- Return on equity
- 88.6%
- Return on assets
- −141.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 259.1%
- Debt / equity
- —
- Book value / share
- $-0.35
- Revenue growth (YoY)
- 80.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -155.39distress
- Accruals / assets
- −47.7%clean
- Beneish M-Score
- -4.97normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TWIRLAFeb 14, 2020
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Mastrangeli DougPassive (13G)Aug 26, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Gilmore GeoffreyOfficer — Chief Administrative Officer | Aug 26, 2024 | D | 10,125 | $1.52 |
| Coiante Scott MOfficer — Chief Financial Officer | Aug 26, 2024 | D | 15,000 | $1.52 |
| Conway Robert GOfficer — Chief Supply Chain Officer | Aug 26, 2024 | D | 10,125 | $1.52 |
| Korner PaulOfficer — Chief Medical Officer | Aug 26, 2024 | D | 10,125 | $1.52 |
| Welsh AmyOfficer — Chief Commercial Officer | Aug 26, 2024 | D | 10,125 | $1.52 |
| Torrente JosephineDirector | Aug 26, 2024 | D | 13 | $1.52 |
| Barbari SharonDirector | Aug 26, 2024 | D | 973 | $1.52 |
| Carson SandraDirector | Aug 26, 2024 | D | 973 | $1.52 |
| Altomari AlfredOfficer — Chief Executive Officer | Aug 26, 2024 | D | 28,125 | $1.52 |
| Fischer Seth H. Z.Director | Aug 26, 2024 | D | 976 | $1.52 |
| Hubbard John WDirector | Aug 26, 2024 | D | 976 | $1.52 |
| Coiante Scott MOfficer — Chief Financial Officer | Oct 3, 2023 | Grant | 20,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteAug 26, 2024
- Entered a material agreement · Regulation FD disclosureJun 26, 2024
- Entered a material agreementMay 21, 2024
- Results of operationsMay 15, 2024
- Results of operations · Regulation FD disclosureApr 9, 2024
- Results of operationsMar 28, 2024
- Delisting / listing-standard notice · Other material eventMar 25, 2024
- Other material eventMar 14, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 13, 2024
- 15-12GSep 30, 2024
- RWAug 28, 2024
- EFFECTAug 27, 2024
- EFFECTAug 27, 2024
- EFFECTAug 27, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
- 4OWNERSHIP DOCUMENTAug 26, 2024
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.